Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Profile Name | JAK3 V718L |
Gene Variant Detail | |
Relevant Treatment Approaches |
Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|---|
JAK3 V718L | esophagus adenocarcinoma | sensitive | Pacritinib | Preclinical - Patient cell culture | Actionable | In a preclinical study, Vonjo (pacritinib) inhibited viability of cells derived from the brain metastases of a patient with esophagus adenocarcinoma harboring JAK3 V718L in culture (PMID: 38985431). | 38985431 | |
JAK3 V718L | esophagus adenocarcinoma | sensitive | Quizartinib | Preclinical - Patient cell culture | Actionable | In a preclinical study, Vanflyta (quizartinib) inhibited viability of cells derived from the brain metastases of a patient with esophagus adenocarcinoma harboring JAK3 V718L in culture (PMID: 38985431). | 38985431 | |
JAK3 V718L | esophagus adenocarcinoma | sensitive | Momelotinib | Preclinical - Patient cell culture | Actionable | In a preclinical study, Momelotinib (CYT387) inhibited viability of cells derived from the brain metastases of a patient with esophagus adenocarcinoma harboring JAK3 V718L in culture (PMID: 38985431). | 38985431 | |
JAK3 V718L | esophagus adenocarcinoma | sensitive | Fedratinib | Preclinical - Patient cell culture | Actionable | In a preclinical study, Inrebic (fedratinib) inhibited viability of cells derived from the brain metastases of a patient with esophagus adenocarcinoma harboring JAK3 V718L in culture (PMID: 38985431). | 38985431 |